Lipid Lowering Combination Therapy for Dyslipidemia
- 1st Edition - January 1, 2027
- Latest edition
- Editor: Maciej Banach
- Language: English
Lipid Lowering Combination Therapy for Dyslipidemia provides clinicians, researchers, and healthcare professionals with practical, up-to-date guidance on the diagnosis and manage… Read more
Description
Description
Key features
Key features
- Highlights cutting-edge advancements and technologies in cardiometabolic disease research and care
- Presents case studies and real-world applications to bridge theory and clinical practice
- Promotes evidence-based approaches for diagnosis, treatment, and prevention
Readership
Readership
Table of contents
Table of contents
II. Lipid Disorders: Cardiovascular Risk and Disease Progression
1. Causal link between hypercholesterolemia and cardiovascular disease risk and mortality
2. Lipid disorders and atherosclerosis/atheroma plaque progression and vulnerability
3. Residual cardiovascular risk related to lipid disorders
III. Diagnostic Approaches and Emerging Biomarkers in Lipid Disorders
4. Current guidelines on lipid disorders diagnosis
5. New lipid targets and their role in lipid disorders
IV. Therapeutic Strategies and Guidelines in Lipid Management
6. The concept of the combination lipid lowering therapy for hypercholesterolemia
7. Risk stratification methods and imaging methods to support decision on lipid lowering therapy intensification
8. Use of Combination Statin and Bile Acid Sequestrant Therapy to Treat Dyslipidemia - is there any place for this?
9. Statins and Niacin: is this really an end?
10. Statins and Ezetimibe – synergistic power to fight against hypercholesterolemia?
11. Statins and bempedoic acid – not only statin intolerant patients!
12. Statins and PCSK9 Inhibitors: Why still so limited?
13. Statins and inclisiran – lets define the most suitable patients waiting for CVOT data
14. Statins and CETP Inhibitors: a game-changer reborn?
15. Lipid lowering combination therapy for patients with familial hypercholesterolemia
15.1. Statins and Mipomersen: Mechanisms of Action and Patient Tolerability
15.2. Statins and Lomitapide: A Suitable Response for Homozygous Familial Hypercholesterolemia?
15.3. Statins and Evinacumab – what patients may benefit the most
16. Lipid lowering combination therapy for statin intolerant patients
17. Other perspective drugs for hypercholesterolemia (oral PCSK9, Lerodalcibep, and others)
18. Lipid lowering combination therapy for hypertriglicerydemia
18.1. Statins and fenofibrate: Still effective and underused
18.2. The Role of Omega-3 Fatty Acids in Dyslipidemias
18.3. New drugs for HTG and SHTG: volanesorsen, olezarsen, pegozafermin, plozasiran, and solbinsiran
19. Recommendations for elevated Lp(a) diagnosis and management
19.1. Pelacarsen
19.2. Muvalaplin
19.3. SiRNA therapies – Olpasiran, lepodisiran and zerlasiran
20. Lipid-Lowering Therapy and Apheresis: Indications and Outcomes
21. Personalized combination LLT in patients with metabolic disorders
22. The concept of the upfront combination LLT – the waiting gold standard to fight against hypercholesterolemia
23. Single pill combination – the more frequent the better to effectively prevent cardiovascular health
24. Combination of Lipid-Lowering Agents with Antihypertensive Drugs: A Joint Fight Against the Two Most Important Risk Factors?
25. Combination of Lipid-Lowering Agents with Aspirin – is there a place in primary prevention patients?
26. Other existing, perspective or expected combination therapies to improve CVD prevention
V. Innovation and Future Directions in Lipid-Lowering Therapies
VI. Summary, Clinical Implications, and Future Perspectives
Product details
Product details
- Edition: 1
- Latest edition
- Published: January 1, 2027
- Language: English
About the editor
About the editor
MB
Maciej Banach
Prof. Maciej Banach is a Vice-Rector for Collegium Medicum in the John Paul II Catholic University of Lublin (KUL) and Head of Department of Preventive Cardiology and Lipidology at the Medical University of Lodz (MUL). He is also an Adjunct Professor at the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, and Senior Research Fellow at the Liverpool Centre for Cardiovascular Sciences (LCCS). He is a Founder and Head of the Polish Lipid Association (PoLA), Founder of the Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group, and President of the International Lipid Expert Panel (ILEP). Prof. Banach is within 1% the highest cited scientists in the world according to Essential Science Indicators by Clarivate (with 83 TOP Papers) and one of the most cited scientist in Poland. He is a laureate of several prizes and award, including: the Most Influential Person in Medicine in Poland for year 2023 with 2nd place for year 2024 on the Top 100 list by Puls Medycyny journal, and 5 recognitions of Doctor Honoris Causa (at the Universities in Zagreb, Kosice, Bucharest, Kiev, and Timisoara).